BioProcessI N T E R N A T I O N A L

The success of the biopharmaceutical industry depends upon your expertise.Depend on BioProcess International to deliver it to your target market.

2015 Media Planner

TM

Editorial Mission

BioProcess International’s editorial staff has a combined 50 years’ biotechnology writing and partnering experience ensuring every issue delivers only the most pertinent information necessary to tackle today’s process challenges while providing a clear vision of the trends that will impact the future bioprocess

BioProcess International’s relies heavily upon its distinguished 30 member Editorial Advisory Board, comprised of leading expertise in every facet of biopharmaceutical research, development, and manufacture to peer review every submitted technical manuscript and ensure each published article exceeds our high editorial standards for accuracy and relevancy.

BioProcess International is dedicated to delivering the most educational, applicable information in three primary formats:

Letter from Publisher

Today’s competitive financial and market conditions demand that biopharmaceutical companies continue to innovate, create and deliver on milestones as promised.

In addition to strengthening and improving their robust protein and MAb pipelines, biopharmaceutical companies must continue to invest, develop, and broaden their R&D efforts and product pipelines with what many are calling the next generation of biopharmaceuticals, which include ADCs, Biosimilars, Biobetters, Cell/Gene/Tissue Therapies, and Vaccines.

To fulfill their therapeutic promise and business expectations, biopharmaceutical companies must continually find ways to improve existing expression and delivery platforms, streamline development and manufacturing processes; implement new operational efficiencies; increase product yields and reduce overall cost of treatment to ensure patient availability and reimbursement.

As premier suppliers to the biopharmaceutical industry, it always has, and always will be your innovations, your science, your technologies, your expertise and partnerships that will ultimately determine how successful the industry can be.

As the premier scientific publication to the biopharmaceutical industry, it is BioProcess International’s responsibility to effectively introduce, communicate and deliver your solutions and expertise to our 30,000+ qualified decision makers.

Delivering your expertise is where BioProcess International excels.

This is our expertise.

Please take a few minutes to review BioProcess International’s 2015 media planner. Each page details, reinforces and supports our philosophy and mission to:

• Acquire, author, and publish the most applicable, cutting- edge biopharmaceutical science, technologies and trends driving process efficiencies and industry growth;

• Develop and maintain the best qualified, most diversified group of international biopharmaceutical professionals and decision makers;

• Consistently improve and expand our print, electronic and interactive lead generating product portfolio to ensure your expertise is surrounded and supported by the most appropriate, well-rounded, well-balanced, well-timed educational content available.

Editorial Experience, Integrity and Peer Review

Technical Articles: peer-reviewed 1,500-4,000 word papers written by established industry experts that provide an educational perspective on the business and applied technologies of biotherapeutic development.

Focus-On Articles: non-technical 1,500-4,000 word papers that examine operational issues and challenges impacting biopharmaceutical companies, including: Regulatory/Quality Issues, Risk Mitigation, Bioethics, Compliance, Legal Issues, Management Strategies, Biotech Business, Training and Careers.

Vendor Voice Articles: peer-reviewed, supplier-written articles that review applicable cutting-edge methodologies and science specific to a company’s technological expertise, products and services.

To our existing advertising partners:

We thank you for your continued support and use of BioProcess International. We look forward to expanding our partnership with you in 2015 and working together to ensure BioProcess International continues to deliver the impact and results your expect from your preferred partner publication.

To our new and prospective advertising partners:

Contact your BPI sales manager to discuss how we can create a customized marketing program that fits into your budget and delivers the return on your investment you require and expect.

The future success of the biopharmaceutical industry depends on incorporating your technologies and expertise. Depend on BioProcess International to deliver it to your target market.

We look forward to partnering with you!

Brian Caine Co-Founder and Publisher

BioProcess International is dedicated to the application of biotechnology to industry, particularly to the applied research, development and manufacture of biopharmaceutical products, including: all proteins, peptides, antibody/non-antibody’s, ADCS, biosimilars, vaccines, cell, gene and tissue therapies, and biodiagnostics.Since 2003, BioProcess International has educated the industry on the business and applied technologies of biotherapeutic development in global setting, including:

Upstream Processing • Expression Platforms • Single-Use Technologies • Fermentation • Cell Culture Media • Assays • Biochemicals/Raw Materials • Contract Services

Downstream Processing • Separation and Purification • Filtration • Chromatography • Single-Use Technologies • Contract Services

Manufacturing • Facility Design and Engineering • Logistics • Supply Chain • Information Technology • Formulation • Fill and Finish • Contract Services

Analytical Methods & Instrumentation • Product Characterization • (Pre) Formulation • Upstream Validation • Upstream Development • Culture Development • Cell Line Development • Downstream Validation • Downstream Development

1 Year: 7.2%

2 Years: 18.1%

3 Years: 21.7%

4 Years: 14.1%

>5 Years: 38.8%

Reader Feedback*

97.9% of readers rate the quality of content published in BioProcess International as Excellent, Very Good, or Good

How would you rate the quality of information BioProcess International provided on the following topics in 2013-2014?

What issue format(s) of BioProcess International do you find most useful/interesting?

What article format(s) of BioProcess International do you find most useful/interesting?

How long have you been receiving BioProcess International?

Fair/Poor: 2.1%Excellent/Very Good: 73.9%

Technical Articles: 71.6%

Focus-On Articles: 56.4%

Ask The Expert: 40.9%

Spotlight: 14.8%

Vendor Voice: 10.6%

Good: 24.0%

Regular Technical Issues: 83.8%

Technical Supplements: 43.2%

Special Reports: 34.2%

Yearbook: 16.9%

BioExecutive Issue (Dec): 16.2%

Poster Hall: 12.8%

TOPIC Excellent/VeryGood Good Fair/Poor

Upstream Processing Technologies 65.5% 31.7% 2.8%

Downstream Processing Technologies 67.7% 28.6% 3.7%

Manufacturing Strategies 59.2% 36.3% 4.6%

Analytical Methods/Instrumentation 55.0% 40.8% 4.2%

QA/QC 51.9% 40.9% 7.3%

QbD 49.8% 42.8% 7.5%

Biopreservation 36.7% 48.9% 13.6%

Supply Chain 43.3% 44.7% 12.0%

Logistics 42.4% 46.4% 11.3%

Single-Use Technologies 64.2% 32.8% 2.9%

Process Development/Design 60.6% 34.6% 4.7%

Outsourcing 46.5% 44.6% 8.9%

Vaccines 43.2% 48.0% 8.7%

Biosimilars/Biobetters 45.1% 45.2% 9.6%

ADCs 45.8% 43.6% 10.7%

Cell/Gene Therapies 44.2% 45.2% 10.6%

Validation 47.5% 44.9% 7.5%

Regulatory Trends/Issues 51.3% 39.9% 8.8%

Business Trends/Issues 52.2% 39.6% 8.2%

Facility/Cleanroom Design/Eng 46.9% 44.1% 9.1%

Bioethics 37.1% 46.9% 16.1%

Legal Trends/Issues 39.7% 42.3% 18.1%

Training and Careers 35.4% 47.1% 17.5%

General Industry News 54.3% 38.9% 6.8%* Source: 2014 BioProcess International Readership Survey

Buyer Intention Trends*

BIOCHEMICALS/RAW MATERIALS

MAbs 42.3%

Proteins 49.2%

Peptides 35.0%

Reagents 71.1%

DNA/RNA 41.3%

Detergents 51.8%

Antigens 32.1%

Enzymes 50.0%

Media/Sera 51.0%

Biochemicals 60.4%

Buffers 64.0%

Viruses/Bacteria 32.7%

UPSTREAM PROCESSING EQUIPMENT AND SUPPLIES

Bioreactors 38.5%

Media 57.1%

Mammalian Cell Culture Systems/Services 37.5%

Cell Separation Systems 33.3%

Cell Banking 23.9%

Fermentors 28.4%

Media Supplements 48.1%

ANALYTICAL METHODS, INSTRUMENTATION, SERVICES

Testing 54.6%

Methods Development 46.7%

DOWNSTREAM PROCESSING EQUIPMENT AND SUPPLIES

Chromatography Columns 50.6%

Chromatography Media 47.7%

Process Chromatography 39.5%

Membranes 50.6%

Filtration Equipment 55.8%

Filters 59.6%

SINGLE-USE TECHNOLOGIES/SYSTEMS

Bags/Bioprocess Containers 46.0%

Bioreactors 33.6%

Mixers 33.6%

Pumps 43.4%

Valves 34.5%

Connectors 47.1%

Piping/Tubing 42.3%

Filters 59.1%

Chromatography 46.3%

Sensors 38.1%

RFID 15.3%

Freezing Solutions 29.7%

CONTRACT, CONSULTING, PHARMACEUTICAL SERVICES

Assay Development 37.2%

Validation 35.3%

Toxicology 22.8%

Biodiagnostic Process 13.4%

Formulation 23.7%

Fill/Finish 16.7%

Analytical Testing 40.5%

QA/QC 29.2%

Product Manufacturing 29.6%

Lyophilization 21.2%

Purification 34.6%

Stability Testing 26.2%

Clinical Trials Management 13.8%

Drug Delivery 13.8%

Business Continuity 20.1%

Process Development 30.6%

Manufacturing Strategy/ Operations 24.9%

Supply Chain Management 19.0%

Program Management 26.1%

Product/Technology Assessment 30.0%

LABORATORY/PROCESS EQUIPMENT

Balances 52.1%

Centrifuges 56.1%

Heating/Cooling Equipment 43.2%

Mixers/Stirrers/Shakers 52.7%

Autoclaves 33.9%

Evaporators 19.0%

Fume Hoods 31.5%

Homogenizers 28.5%

COMPUTER SOFTWARE

Bioinformatics Software 34.1%

Data Acquisition Software 41.0%

Data Management Software 38.4%

Image Analysis/ Processing Software 33.1%

Laboratory Data

Management Software 29.8% LIMS Software 20.7%

Process Control Software 25.5%

Which of the following products/equipment/services have you approved/purchased/recommended over the last 12 months?

How much will your company invest in each of the following products/equipment/services over the next 12 months?

UP TO $100,000 $100,000 – 1,000,000 >$1,000,000

Biochemicals 67.9% 20.2% 11.9%

Upstream Processing Equipment and Supplies 64.8% 22.6% 12.6%

Downstream Processing Equipment and Supplies 63.9% 22.2% 13.9%

Analytical Methods/ Instrumentation/Services 69.4% 23.2% 7.4%

Single-Use Technologies 73.8% 17.0% 9.2%

Contract/Consulting Pharmaceutical Services 76.4% 15.0% 8.5%

Laboratory/Process Equipment 71.0% 21.5% 7.5%

Engineering/Construction/Cleanroom/Logistics 72.3% 14.6% 13.1%

Computer Software 79.4% 13.9% 6.7%* Source: 2014 BioProcess International Readership Survey

Circulation Demographics

Did You Know ?

Primary Business % of Readers

Biological/Biopharmaceutical Manufacturing and Pharmaceutical Companies with Biotech Focus 31.7%

Biological/Biodiagnostic/Biopharmaceutical Process Development 3.1%

Biotechnology/Biopharmaceutical Research 7.1%

Biodiagnostics, Delivery and Other Devices 2.2%

Peptide Therapeutics, Biological Vaccines, Cell Therapies, Oligosand other nonsynthetic Small Molecules 1.8%

Clinical Research Organization/Contract Research and Services/Contract Manufacturing/Services 18.6%

Industrial/Specialty Chemicals/Bulk Products and Raw Materials 3.6%

Engineering 3.1%

Government/Regulatory 9.3%

Business/Investment/Legal Services/Consulting 7.8%

Others Allied to the Field 11.7%

Job Title % of Readers

Supervisor/Director 14.0%

Manager/Section/Lab Manager/Group Leader 29.1%

Senior Research/Staff Scientist/ Research Associate, PhD 22.3%

CEO/CFO/COO, Executive VP/VP 15.9%

Engineer/Chemist 6.7%

Senior Analyst/Other Titled Allied to Field 12.0%

Job FunctionResearch/Development 47.4%

Process Development 4.5%

Production/Manufacturing 3.6%

Laboratory Management 5.7%

Project Management 3.9%

Technical/Analytical Services, QA/QC, Validation 7.5%

Engineering 2.2%

Corporate Management/Business Advisor/ Development 14.9%

Regulatory/Clinical Affairs 4.4%

Technology Transfer, IP, Legal, Information Management/Technology 1.4%

Materials Management/Purchasing/ Logistics, Other Functions 4.5%

8.6% 4.1% 6.9% 15.6% 64.8%

3.3% 13.6% 8.1% 22.1% 52.9%

4.9% 20.0% 14.6% 24.9% 35.7%

<1 1-3 4-5 6-10 Years >10 Years Year Years Years Years

<1 1-3 4-5 6-10 Years >10 Years Year Years Years Years

<1 1-3 4-5 6-10 Years >10 Years Year Years Years Years

87.3% of BPI’s readers have more than 4 years’ experience in the biotechnology industry.

83.1% of BPI’s readers have worked for the same company for more than 4 years.

75.1% of BPI’s readers have held their current job title for more than 4 years.

Since 2003, BioProcess International has consistently delivered your technology and expertise to the largest, best qualified international print and digital readership in the industry.

Paragraph 3b details a publication’s qualification source breakout, telling you where a publication obtained the qualified circulation (source) and the period in which these recipients were last qualified (age). BioProcess International has a BPA-audited print circulation consisting of 30,005** mid- to upper-level managers and professionals working on all phases of the biotherapeutic development research, development, and manufacturing process in the United States, Canada, and Europe.

BPA’S INDEPENDENT AUDIT OF BIOPROCESS INTERNATIONAL’S QUALIFIED SUBSCRIBERS — June 2014

BPI’s subscribers were qualified within

1 Year .......... 90%

2 Year .......... 10%

3 Year .............0%

Qualified Print Distribution: 30,005 **Digital Asia-Pacific Distribution: 10,201Digital North America Distribution: 30,128Digital European Distribution: 10,424

TOTAL DISTRIBUTION: 80,758

Circulation Mission

BioProcess International’s 30,005 BPA-audited print subscribers are mid-to-upper level and executive decision makers located in the United States, Europe and Canada responsible for successfully driving biotherapeutic products through the research, development and commercial manufacturing process.

North America: .............22,426 (74.8% of total circulation)

South Atlantic ................................4,073

Middle Atlantic ..............................3,589

East North Central.........................3,200

Pacific ...............................................3,011

New England ..................................2,079

West North Central .......................1,863

West South Central .......................1,856

East South Central ........................1,042

Mountain ........................................... 973

US Territories & Canada .................. 740

Europe: .............................7,569 (25.2% of total circulation)

United Kingdom ............................2,082

Germany .........................................1,171

France ................................................. 784

Belgium .............................................. 571

Switzerland ....................................... 410

Netherlands ...................................... 355

Italy ..................................................... 310

Spain ................................................... 307

Denmark ............................................ 252

Sweden ............................................... 242

Ireland ................................................ 233

All Other EU: ...................................... 852

** Source: June 2014 BPA Worldwide Brand Report

CMC Strategy Forum SeriesSince 2003, BioProcess International and CASSS have partnered to publish a series of 20+ consensus papers based upon The CMC Strategy Forum meetings. In 2015, BioProcess International will combine and publish as four dedicated special reports per the following schedule:

JANUARY: QbD and Quality Risk Management • Quality by Design (QbD) for Biopharmaceuticals • Quality by Design – The Next Phase: Approach for Filing the QbD Data and Potential Regulatory Implications • Practical Applications of Quality Risk Management • QbD for Biologics: Learning from the Product Development and Realization (A-MAb) Case Study and the FDA Pilot Program

APRIL: QbD Manufacturing Strategies

• Multiproduct Facility Design and Control for Biologics: Challenges and Considerations • Drug Products for Biological Medicines: Novel Delivery Devices, Challenging Formulations and Combination Products • New Paradigms for Process Validation: A Practical Approach • Biosimilar Products: Scientific Principles, Challenges and Opportunities

SEPTEMBER: Analysis and Characterization

• Analysis and Structure Characterization of Monoclonal Antibodies • Analytical Characterization and Regulatory Considerations for Antibody-Drug Conjugates: Uniting Small Molecule and Biologic Drug Perspectives • Glycosylation of Therapeutic Proteins: Current Understanding of Structure-Function Relationship • Lot Release and Characterization Testing of Live-Virus-Based Vaccine and Gene Therapy Products

NOVEMBER: Assays, Test Methods and Comparability

• Binding Assays and Bioassays: What are their Roles in Lot Release and Stability Testing • Demonstrating Comparability for Well-Characterized Biotechnology Products: Early Phase and Post Approval • Raw Material Control Strategies for Bioprocesses • The Role of Higher Order Structure in Defining the Quality of Biopharmaceutical Products • What is Test Method Qualification?

Effective Print Vehicles

BioProcess International’s success is derived from its unique ability to consistently acquire, present, and publish the most relatable and applicable scientific information to its 30,005 qualified biopharmaceutical subscribers. Whether it’s a main monthly issue, special report, or supplement, BPIs readers understand and expect that every print issue they receive contains information they can use to improve their current process.

This is where BioProcess International excels. This is our expertise.Effective marketing programs must include a balanced print advertising campaign. Utilize BioProcess International’s portfolio of print educational vehicles to effectively introduce and communicate your expertise, your solutions, to BPIs qualified decision makers – as they are simultaneously reading and learning how to improve their business. Be sure to include easy links to special offers on your website (with a registration requirement), QR codes and unique urls (so you can track leads generated by BPI).

Main Monthly IssuesEach issue is dedicated to one of the three pillars of bioprocessing – Upstream Processing, Downstream Processing, Manufacturing. You can count on two-thirds of Focus-On articles and half of the technical articles to hit the theme. The remaining articles provide BPIs readers with a balanced diversity of information, ensuring every reader finds something interesting they can learn and use in every issue.

Advertising should be either consistently placed on designated pages (based upon availability) within any issue to maximize message visibility and reader impact/recall or strategically placed within articles that specifically target or discuss your technology and expertise. To further separate your company from the competition, consider placing non-traditional advertisements (ex. full or half page spread advertisements, inserts, postcards, etc.).

Special ReportsThese special 7”x 9” digest size reports provide BioProcess International with a custom format to editorially target and educate the market on cutting edge techniques and technologies. Special reports are printed on heavy paper stock, inserted into main issues, and distributed to BPIs 30,000 qualified print and 10,000 Asia-Pacific digital readers.

Advertising is limited to five full page sponsorships on a first reserved basis. All sponsors receive 250 additional copies for marketing usage and each special report is bonus distributed to every conference BPI attends for a full year.

Technical SeriesJANUARY: The Single-Use Watering Hole – Where Innovation Needs Harmonization, Collaboration, and Standardization

This report captures the current challenges of SUT standardization, including company concerns, regulatory expectations, market and cost pressures, and sets a proposed course for SUT users and suppliers to make a collaborative effort to overcome these challenges before they become unmanageable.

FEBRUARY: Vaccines – Challenges and Opportunities for BioProcess Development and Manufacturing

Increased understanding of the human immune system, rapid scientific advancements, available local talent and non-government funding as well as advancements in production and downstream processes are decreasing costs and accelerating vaccine development. This report explores the advances of the last decade and the challenges of the coming decade.

MAY: Current Strategies in Protein Drug Stability

Biotherapies must maintain the same quality, efficacy, and safety throughout development. An unstable protein-drug formulation presents difficult problems for manufacturers and creates specific risks to its desired physical and chemical characteristics. This special report provides a review of current formulation and fill-finish strategies for developing stable drug products.

JUNE: Biosimilars or Biobetters: Navigating Uncertain Waters

The line between a follow-on biologic and an improvement on an established concept can be a fuzzy one. Well-characterized biologics should be reproducible — but modern technologies may give a biosimilar improved quality, safety, and/or efficacy over an originator product, but improvements come with costs of their own.

OCTOBER: High-Throughput Development for Efficient Process Design

Current industry needs for streamlined processes, reduced manufacturing costs, and shortened production timelines have driven the interest in high-throughput development capabilities. This report examines how manufacturers are implementing cutting-edge technologies and strategies across the process floor and throughout entire process design.

DECEMBER: Developability: Drawing the Line Between Discovery and Development

Turning a biological molecule into a viable drug requires determining whether it truly can be made into a product. Early “developability” assessment studies identify problems associated with formulation stability and solubility that could complicate production and processing and help companies identify the best candidates for development.

Special Reports

Supplement Series

Supplement SeriesBPI’s technology and conference supplement series are special full size (8.5 x 11) issues that provide the publication with enough dedicated space to expertly investigate, report, explore and discuss specific products and technologies that are challenging the current status-quo and introducing efficiencies that will impact current and future process and product development. BPI’s technology and conference supplement series are polybagged with scheduled main issues and are also distributed independently throughout the year to targeted scientific conferences and meetings. A properly balanced marketing program should include advertising in targeted BPI’s supplements as they create a unique editorial environment and resource to compliment your expertise and maximize your solutions. Technology Supplement SeriesMARCH: Single-Use: Best Practices for Sourcing, Implementation, and Application

Although single-use technologies are familiar to the biopharmaceutical industry now, key questions remain. BPIs 8th annual single-use supplement focuses on sourcing strategies, supply chain security, safety and compatibility of plastics with drug products (and increasing knowledge about how such materials are made), and application within different industry segments continue to be topics of great interest and importance.

APRIL: Cell Therapies, Part 1: Accelerating Affordable Cell Growth

Technological advances can improve affordability of cell therapies that are well tolerated and efficacious, offering a longer therapeutic effect than treatments based solely on small and large molecules. This supplement explores the current state-of-the-art in cell expansion and bioprocessing along with related efforts to lower overall development and manufacturing costs.

OCTOBER: Cell Therapies, Part 2: Manufacturing Strategies for Commercial Success

Evolving process economics, logistical strategies, and regulatory pathways for cell therapies and other personalized/regenerative medicines are critical to the uptake of these revolutionary therapies. This issue addresses advances in the technical and operational landscape of this market segment, profiling ways in which companies are revolutionizing the future of healthcare.

NOVEMBER: Interactive Poster Hall

Scientific posters are a tremendous resource to biopharmaceutical professionals. Their unique format take scientists and researchers on a visual journey through the latest experiment results and technology performance that can help biopharmaceutical companies improve existing techniques and processes.BioProcess International invites your company to present your latest poster(s) in the newly updated and improved interactive poster hall program. This combined print and interactive online portal provides your company with the unique opportunity to introduce and present your science and technology to our 45,000 biopharmaceutical professionals.

Effective Electronic Vehicles

The New bioprocessintl.com Completely redesigned, BioProcess International’s new website significantly improves the visitor experience. Scientific content is categorized by process and technology, providing our 25,000+ monthly biopharmaceutical professional visitors with an interactive experience, improved navigation, enhanced search features. The new design effectively positions, supports and drives qualified leads to all your electronic expertise, including: banner ads, white papers, enriched media, webcasts, and posters.

The New eNewsletter SeriesCompletely redesigned to compliment BPI’s new website, the eNewsletter Series electronically delivers targeted and themed scientific information on a weekly schedule to 30,000+ biopharmaceutical professionals in North America, Europe, and Asia-Pacific. Each eNewsletter focuses on the three main pillars of bioprocessing: the upstream processing, downstream processing and manufacturing. eNewsletter sponsors are limited to six per edition.

Ask the Expert Webcast Series This unique turnkey program combines the lead generation of a traditional webcast with the prominence of a published full page article in BioProcess International. The program begins with a ten minute webcast followed by a five minute Q&A. This combination provides your company with an effective opportunity to introduce your equipment and expertise, generate qualified leads, and directly interact and engage in Q&A with BPI’s readers. The webcast is recorded, then transcribed, edited and published as a full page Ask the Expert article in a pre-determined issue BioProcess International.

Electronic Press Releases Available in straight text or HTML format, BPIs ePR capabilities provide your company with an effective delivery vehicle to educate the industry on your company’s latest product launches, corporate initiatives, etc.

A balanced marketing strategy is key to generating the results and ROI you demand and expect. While print advertising is necessary to introduce and support your expertise, brand recognition and overall market leadership, online and electronic advertising is necessary to specifically explain how your technologies, products, and solutions can improve existing research, development and manufacturing operations at leading biopharmaceutical companies.BioProcess International offers a unique and diversified a portfolio of online, electronic and interactive products designed to effectively deliver your solutions and generate qualified leads from BPI’s 25,000+ electronic readers in North America, Europe and Asia-Pacific.

CMC Strategy Forum QBD and

Quality Risk Management

CMC Strategy Forum QBD

ManufacturingStategies

CMC Strategy Forum Analytics

andCharacterization

CMC Strategy Forum Assays, Test

Methods, and Comparability

Special ReportThe Single-Use Watering Hole

Special Report

VaccinesSpecial Report

ProductStability

Special ReportBiosimilarsBiobetters

Special ReportHigh Throughput

Development

Special Report

Developability

Special Report – CMC Strategy Forum Series

Special Report – Technical Series

Targeted Ad Packages

Closing Deadline December 12 January 9 February 9 March 10 April 10 May 8 June 19 August 10 September 7 October 9 November 9

Materials Deadline December 15 January 14 February 13 March 16 April 15 May 15 July 10 August 17 September 14 October 14 November 15

January February March April May June August September October November December

Supplement – Conference

Series

Conference SupplementBPI

EU Summit

Conference SupplementBIO/BioProcess Zone Pre-Event

Planner

Conference Supplement2015

BPI TheaterSeries

Conference SupplementBPI Conference

Pre-EventPlanner

Conference Supplement2016

Industry EventCalendar

Supplement – Technology

Series

Technology SupplementSingle-Use

Sourcing, Implementa-tion, and Application

Technology Supplement Cell Therapies

Accelerating Affordable Cell Growth

includes

ISCT 2015 Special Report

Technology Supplement

Cell Therapies – Implementing a Successful

Manufacturing Strategy

Technology SupplementPoster Hall

Targeted Ad PackageBDP Week

Supplier Profiles

Targeted Ad PackageBPI Theater

@ INTERPHEX

Targeted Ad PackageESACT

Supplier Profiles

BPI Theater @ Phacilitate

Vax 1-2-1

Targeted Ad PackageBPI Theater

@BIO

Key Show

CASSS BioAssaysMarch 23-25

BDP WeekMarch 30-April 2

Key Show

BPI European SummitApril 14-15

INTERPHEX 2015April 21-23

TIDESApril 21-23

CMC Strategy ForumMay 4-6

PEGSMay 4-9

Key Show

ISCT Annual Meeting

May 27-30

Key Show

BIO International ConventionJune 15-18

Key Show

BPSA Single-Use

SummitJuly 13-15

Key Show

IBC Cell Therapy

BioProcessing

PDA Joint Regulatory

Conference

Key Show

BioProcess International Conference

October 26-29

Informa BioProduction

ISPE

PEGS Europe

Key Show

AAPS

Key Show

IBC Antibody

Engineering

Informa Vaccines/Cell-Gene Therapy

Key Shows

UpstreamProcessing

DownstreamProcessing Manufacturing Upstream

ProcessingDownstream

Processing Manufacturing Yearbook UpstreamProcessing

DownstreamProcessing Manufacturing

The BioExecutive

Issue

Main Monthly Issue

Key Show

WCBPJanuary 27-29

CMC Strategy ForumJanuary 26

Bioleaders ForumJanuary 26-28

Key Show

IBC Asia TIDESMarch 2-5

Editorial CalendarJanuary - May 2015

BioProcessI N T E R N A T I O N A L

TM

Editorial CalendarJune - December 2015

BioProcessI N T E R N A T I O N A L

TM

Includes Ads in Conference Issue and Special Report, Roadmap Profile, and Speaking Slot)

* Gross rates include 15% agency fee

• PMS/Metallic/Flourescent Colors - add $1,000

** Additional 5% discount if using same creative

for multiple placements

Sales Contact Information

Brian J. Caine Publisher 1-508-904-7259 bcaine@bioprocessintl.comChristopher Johnson Eastern Regional Sales Manager 1-508-614-1273 cjohnson@bioprocessintl.comMike Kelly Western Regional Sales Manager 1-646-957-8974 mkelly@bioprocessintl.comJoanna Taylor European & Asia-Pacific Sales Manager +44 (0)20 7551 9392 joanna.taylor@informa.com

Main Issues/ Technology & Conference Supplements

2015 Print Rates USD ($) Gross/Standard 4C*

CMC Forum/Special Reports(Digest Size)

BPI Theater PackageINTERPHEX, BIO, PHACILITATE

Conference 1/3 Page ProfilesBDP WEEK, ESACT

1x 3x Non-Active BPI Advertiser $3,000 $2,500 Active BPI Advertiser $2,400 $2,000

1x 3x 6x 9x Full Page $9,500 $9,250 $9,025 $8,550 1/2 Page (Island/Horizontal/Vertical) $7,600 $7,400 $7,225 $6,850

Web Banners

MultimediaWhite Papers/Podcasts

Ask The ExpertWebcast

eNewsletter

1x 2-3x 4-6x 7-11x 24x Top Leaderboard $3,825 $3,650 $3,475 $3,235 $2,975 Bottom Leaderboard $2,650 $2,500 $2,475 $2,235 $2,075 MPU1 $3,235 $3,075 $2,900 $2,700 $2,425 MPU2 (Home Page Only) $2,100 $1,955 $1,855 $1,700 $1,550 Skyscraper $2,950 $2,800 $2,655 $2,455 $2,205

30 Days 60 Days 90 Days 180 Days 12 Months 1X $1,500 $2,000 $2,500 $3,050 $3,750 2X per $1,175 $1,600 $2,175 $2,650 $3,275 3X per $925 $1,325 $1,700 $2,250 $2,950 4X per $650 $1,075 $1,425 $2,000 $2,475

2015 Online/Electronic Rates

Asia Pacific eNewsletter(includes HTML sponsorship)

HTML

1x 3x 6x 12x Top Leaderboard 1,200 1,150 1,100 1,000 Bottom Leaderboard 1,100 1,050 950 850 MPU1 1,100 1,050 950 850 MPU2 (Home Page Only) 700 650 600 500 Skyscraper 1,100 1,050 950 850

1x 3x 6x Full Circulation $6,000 $5,500 $5,000 Half Circulation $4,000 $3,500 $3,000 Asia Pacific $3,000 $2,500 $2,000

1x 3x 6x 12x Upstream/Downstream/Manufacturing $2,100 $1,800 $1,600 $1,200

1x 2x 3x 4x Webcast Only $7,060 $7,060 $7,060 $7,060 Webcast + Full Page Article $11,750 $11,175 $10,580 $9,425

1x 3x 6x 12x 24x Full Page $9,520 $9,375 $9,045 $8,570 $8,090 1/2 Page (Island/Horizontal/Vertical) $7,540 $7,425 $7,165 $6,785 $6,410 1/3 Page (Square/Horizontal/Vertical) $5,770 $5,685 $5,480 $5,195 $4,905 1/4 Page $5,040 $4,965 $4,790 $4,535 $4,285 French Door ** $19,500 $19,250 $18,825 N/A N/A Insert (single page/2-sided) ** $14,500 $13,375 $12,750 N/A N/A

1x 3x Full Page $15,000 $14,000 1/2 Page (Island/Horizontal/Vertical) $13,000 $12,000